DMRA
NASD Damora Therapeutics, Inc.$0.0000 ↓ -20.2550 (-100.00%) Trading Down from the previous close of $20.2550
- YTD change
- N/A
- vs 20-day SMA
- N/A
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-6.18 (-23.36%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $38.3251
- DMRA is down 100% since the beginning of the year
- DMRA is down 100% over the past 12 months
- DMRA is down 100% over the past 1 month
- 8% of all DMRA investors are betting against DMRA
DMRA reads poor: the 12-month move is -20.6%.
- Previous minute
- N/A
- Last hour
- N/A
- Last 5 days
- N/A
- vs 8-day SMA
- N/A
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Waltham, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
